Pfizer Inc (PFE) 29.57 $PFE
Most active New York Stock Exchange-traded stocks
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Tue Sep 30, 5:03PM CDT
___
Drug and device firms paid $3.5B to care providers
By RICARDO ALONSO-ZALDIVAR and JACK GILLUM - AP - Tue Sep 30, 4:54PM CDT
WASHINGTON (AP) — From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed Tuesday in a new effort to spotlight potential ethical conflicts in medicine.
GlycoMimetics Down Due to Delay in Rivipansel Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 2:10PM CDT
GlycoMimetics Inc. (GLYC) announced that the initiation of a phase III study on rivipansel (to be conducted by its partner Pfizer Inc.) will be delayed indefinitely.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Watch for Shares of Pfizer (PFE) to Approach Resistance at $30.00
Comtex SmarTrend(R) - Tue Sep 30, 10:13AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $29.73 today and have reached the first resistance level of $29.88. Investors may be interested in a cross of the next upside pivot targets of $30.00 and $30.27.
Early Glance: Pharmaceuticals companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher
PR Newswire - Tue Sep 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6854-100free.
Glaucoma Treatment Market 2014-2019 Global Trends & Opportunities Reviewed in New Research Report
PR Newswire - Tue Sep 30, 7:30AM CDT
MarketReportsOnline.com adds Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) research report that provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Complete report is available at http://www.marketreportsonline.com/357921.html .
Hospital Infection Therapeutics (Antibacterial, Antiviral and Antifungal Drugs) Market - Global Pipeline Analysis 2014-2020
M2 - Tue Sep 30, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q7d8p/hospital) has announced the addition of the "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future. North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region. The global hospital infection therapeutics market is segmented as follows: Hospital Infection Therapeutics Market, by Drug Type - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs Hospital Infection Therapeutics Market, by Major Infections - Hospital-Acquired Pneumonia - Surgical Site Infections - Urinary Tract Infections - Gastrointestinal Disorders - Bloodstream Infections - Other Hospital Infections Companies Mentioned - Actavis plc - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/4q7d8p/hospital
Viagra ads target women for 1st time
By LINDA A. JOHNSON - AP - Tue Sep 30, 11:30AM CDT
TRENTON, N.J. (AP) — The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial that targets the less-obvious sufferers of the sexual condition: women.
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
Business Wire - Mon Sep 29, 7:00PM CDT
Pfizer Inc. (NYSE FE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors.
Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 7:51AM CDT
Source: Images Money via Flickr . According to Susanna Kim of ABC News, dividend yield and dividend growth comprised 90% of the total nominal returns for investors in the S&P 500 between 1910 and 2010. You might rightly proclaim that...
Market Maker Surveillance Report. NLY, ANR, PFE, ITMN, FNMA, ZNGA, Highest Net Sell Volume and Negative Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Friday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Annaly Capital Management Inc (NYSE:NLY), Alpha Natural Resources Inc (NYSE:ANR), Pfizer Inc (NYSE FE), InterMune Inc (NASDAQ:ITMN), Federal National Mortgage Association (OTC:FNMA), Zynga Inc (NASDAQ:ZNGA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
This Is the Last Thing You'd Expect a Tobacco Company To Do
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 3:33PM CDT
Source: Flickr user Marlus Mellebye. To put it succinctly, the tobacco industry is in flux. On one hand, tobacco is a highly addictive substance that, almost regardless of pricing, seems to keep bringing smokers back for more. Despite the...
High Blood Pressure Is Most Prevalent in These 5 States
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 11:34AM CDT
Source: Flickr user HazPhotos. There are few diseases that get as much attention in the U.S. as cancer – and with good reason as it's a lethal disease in many instances which often doesn't have a cure. However, there's an equally dangerous...
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
Most active New York Stock Exchange-traded stocks
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Tue Sep 30, 5:03PM CDT
___
Drug and device firms paid $3.5B to care providers
By RICARDO ALONSO-ZALDIVAR and JACK GILLUM - AP - Tue Sep 30, 4:54PM CDT
WASHINGTON (AP) — From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed Tuesday in a new effort to spotlight potential ethical conflicts in medicine.
GlycoMimetics Down Due to Delay in Rivipansel Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 2:10PM CDT
GlycoMimetics Inc. (GLYC) announced that the initiation of a phase III study on rivipansel (to be conducted by its partner Pfizer Inc.) will be delayed indefinitely.
Midday Glance: Pharmaceuticals companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Watch for Shares of Pfizer (PFE) to Approach Resistance at $30.00
Comtex SmarTrend(R) - Tue Sep 30, 10:13AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $29.73 today and have reached the first resistance level of $29.88. Investors may be interested in a cross of the next upside pivot targets of $30.00 and $30.27. Early Glance: Pharmaceuticals companies
AP - Tue Sep 30, 9:41AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher
PR Newswire - Tue Sep 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6854-100free.
Glaucoma Treatment Market 2014-2019 Global Trends & Opportunities Reviewed in New Research Report
PR Newswire - Tue Sep 30, 7:30AM CDT
MarketReportsOnline.com adds Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) research report that provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Complete report is available at http://www.marketreportsonline.com/357921.html .
Hospital Infection Therapeutics (Antibacterial, Antiviral and Antifungal Drugs) Market - Global Pipeline Analysis 2014-2020
M2 - Tue Sep 30, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4q7d8p/hospital) has announced the addition of the "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future. North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region. The global hospital infection therapeutics market is segmented as follows: Hospital Infection Therapeutics Market, by Drug Type - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs Hospital Infection Therapeutics Market, by Major Infections - Hospital-Acquired Pneumonia - Surgical Site Infections - Urinary Tract Infections - Gastrointestinal Disorders - Bloodstream Infections - Other Hospital Infections Companies Mentioned - Actavis plc - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline plc - Johnson & Johnson Services, Inc. - Merck & Co., Inc. - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/4q7d8p/hospital
Viagra ads target women for 1st time
By LINDA A. JOHNSON - AP - Tue Sep 30, 11:30AM CDT
TRENTON, N.J. (AP) — The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial that targets the less-obvious sufferers of the sexual condition: women.
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
Business Wire - Mon Sep 29, 7:00PM CDT
Pfizer Inc. (NYSE
FE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 29, 7:51AM CDT
Source: Images Money via Flickr . According to Susanna Kim of ABC News, dividend yield and dividend growth comprised 90% of the total nominal returns for investors in the S&P 500 between 1910 and 2010. You might rightly proclaim that...
Market Maker Surveillance Report. NLY, ANR, PFE, ITMN, FNMA, ZNGA, Highest Net Sell Volume and Negative Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Friday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Annaly Capital Management Inc (NYSE:NLY), Alpha Natural Resources Inc (NYSE:ANR), Pfizer Inc (NYSE
FE), InterMune Inc (NASDAQ:ITMN), Federal National Mortgage Association (OTC:FNMA), Zynga Inc (NASDAQ:ZNGA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . This Is the Last Thing You'd Expect a Tobacco Company To Do
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 3:33PM CDT
Source: Flickr user Marlus Mellebye. To put it succinctly, the tobacco industry is in flux. On one hand, tobacco is a highly addictive substance that, almost regardless of pricing, seems to keep bringing smokers back for more. Despite the...
High Blood Pressure Is Most Prevalent in These 5 States
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 27, 11:34AM CDT
Source: Flickr user HazPhotos. There are few diseases that get as much attention in the U.S. as cancer – and with good reason as it's a lethal disease in many instances which often doesn't have a cure. However, there's an equally dangerous...
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
